Brian Na, Anthony C Wang, Christopher Travis Watterson, Julian Martinez-Agosto, Sulagna Saitta, Marina Dutra-Clarke, Franceska Bhansali, Stacy L Pineles, Vivian Y Chang, Veeral S Shah, Peter de Blank
Crouzon Syndrome is a genetic craniosynostosis disorder associated with a high risk of ophthalmologic sequelae secondary to structural causes. However, ophthalmologic disorders due to intrinsic nerve aberrations in Crouzon Syndrome have not been described. Optic pathway gliomas (OPGs) are low grade gliomas that are intrinsic to the visual pathway, frequently associated with Neurofibromatosis type 1 (NF-1). OPGs involving both optic nerves without affecting the optic chiasm are rarely seen outside of NF-1. We report an unusual case of bilateral optic nerve glioma without chiasmatic involvement in a 17-month-old male patient with Crouzon Syndrome without any clinical or genetic findings of NF-1...
June 19, 2023: Pediatric Hematology and Oncology
Aude Givone, Jean Duval-Destin, Mathilde Delebarre, Wadih Abou-Chahla, Cyril Lervat, François Dubos
Our aim was to identify national consensus criteria for the management of children with chemotherapy-induced febrile neutropenia (FN), for evidence-based step-down treatment approaches for patients classified at low risk of severe infection. In 2018, a five-section, 38-item survey was e-mailed to all pediatric hematology and oncology units in France ( n  = 30). The five sections contained statements on possible consensus criteria for the (i) definition of FN, (ii) initial management of children with FN, (iii) conditions required for initiating step-down therapy in low-risk patients, (iv) management strategy for low-risk patients, and (v) antibiotic treatment on discharge...
June 9, 2023: Pediatric Hematology and Oncology
Doli Das, Vikas V Singh, Sudhir K Chauhan, Richa Rai, Ashok Kumar, Madhu Jain, Geeta Rai
Low birth weight (LBW) is a leading cause of newborn's mortality however the underlying defects in cellular immunity and immune mechanisms leading to severe neonatal infections in term LBW (tLBW) newborns are not well understood. Neutrophil extracellular traps (NETs), or NETosis, is an innate immune defense mechanism of neutrophils involved in trapping and killing of microbes. The efficiency of NET formation in cord blood derived neutrophils of tLBW and normal birth weight (NBW) newborns in the presence of toll like receptor (TLR) agonist inductions was evaluated...
June 8, 2023: Pediatric Hematology and Oncology
Dilpreet Kaur Banwait, Puneet Rana Arora, Amita Mahajan, Veronique Dinand, Sandeep Jain, Manas Kalra, Jagdish Chandra, Ramandeep Singh Arora
No abstract text is available yet for this article.
June 2, 2023: Pediatric Hematology and Oncology
Biljana Škorić, Miloš Kuzmanović, Marija Jovanović, Branislava Miljković, Dragan Micić, Milena Jović, Ankica Jovanović, Katarina Vučićević
Monitoring and optimization procedures improved high dose methotrexate (HDMTX) treatment outcomes. However, there are still some concerns regarding unexplained concentration variability. The objective of this study was to evaluate drug concentrations and associated variability factors in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on HDMTX. Fifty patients (aged 1-18 years), receiving in total 184 HDMTX cycles of 3 or 5 g/m2 /24 h infusion, were included in the study...
May 17, 2023: Pediatric Hematology and Oncology
Yanli Yang, Hanqing Yu, Chenli Li, Zhen Gui, Yong Chang
The aim of the study was to test whether the cytokine profile could be used as a marker to differentiate between Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and Kawasaki disease (KD). A total of 70 hospitalized children with HLH and KD admitted to hospital for the first time from March 2017 to December 2021 were enrolled in this study. Fifty-five healthy children were enrolled as normal controls. All patients and normal controls were tested for the six cytokines including interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and interferon-γ (IFN-γ) by flow cytometry...
May 13, 2023: Pediatric Hematology and Oncology
Erlyn Smith, Chandra Krishnan
Mixed phenotype leukemia (MPAL) is a rare type of acute leukemia with blasts that co-express antigens of more than one lineage on the same cell or that have separate populations of blasts of different lineages. Here, we report a five-year-old male with inguinal lymphadenopathy diagnosed with MPAL-T/Myeloid MPAL-T/M. The clone demonstrated lineage and immunophenotypically distinct blast populations in the bone marrow and lymph nodes. Bone marrow cytogenetic studies confirmed a rare PICALM::MLLT10 gene fusion...
May 12, 2023: Pediatric Hematology and Oncology
Carly Stewart, Kristen McPherson, Liza-Ann Whitaker, Nicholas B Sajjadi, Randi Kerr, Michael A Baxter, Micah Hartwell
Finding safer and more effective treatment options are critical in progressing the field of pediatric oncology. These treatment options are discovered through completion and publication of clinical trials. The primary objective of this study was to assess the overall study characteristics of pediatric oncology clinical trials initiated between 2008 and 2021. The secondary objective of our study was to assess rates of discontinuation and reporting of results as required by the Food and Drug Administration (FDA)...
May 12, 2023: Pediatric Hematology and Oncology
Panagiotis Tsarouhas, Melissa Stalling, Carmen Julius, Jeffrey Hord
No abstract text is available yet for this article.
May 11, 2023: Pediatric Hematology and Oncology
Alexander Ngwube, Angela Garcia, Andrew Ritchey, Lucia Mirea, Sophia Williams, Roberta Adams
No abstract text is available yet for this article.
May 11, 2023: Pediatric Hematology and Oncology
Satoshi Miyamoto, Kevin Y Urayama, Yuki Arakawa, Katsuyoshi Koh, Yuki Yuza, Daisuke Hasegawa, Yuichi Taneyama, Yasushi Noguchi, Masakatsu Yanagimachi, Takeshi Inukai, Setsuo Ota, Hiroyuki Takahashi, Dai Keino, Daisuke Toyama, Junko Takita, Daisuke Tomizawa, Tomohiro Morio, Kazutoshi Koike, Koichi Moriwaki, Yuya Sato, Junya Fujimura, Daisuke Morita, Yujin Sekinaka, Kozue Nakamura, Kazuo Sakashita, Hiroaki Goto, Atsushi Manabe, Masatoshi Takagi
Germline genetic variants influence development of pediatric B cell acute lymphoblastic leukemia (B-ALL). Genome-wide association studies (GWAS) have identified several pediatric B-ALL susceptibility loci. IKZF1 and PAX5 , transcription factors involved in B cell development, have been reported as susceptibility genes for B-ALL development. Therefore, we hypothesized that rare variants of genes involved in B cell development would be candidate susceptibility loci for pediatric B-ALL. Thus, we sequenced TCF3 , a key transcription factor gene involving in B cell development...
May 2, 2023: Pediatric Hematology and Oncology
Charles Nathaniel Nessle, Tom Braun, Vineet Chopra, Sung Won Choi, Rajen Mody
During COVID-19, public health measures including masks and social distancing decreased viral upper respiratory infections (URI). Upper respiratory infections are the most common infectious etiology for low-risk pediatric febrile neutropenia (FN). This single-center, quasi-experimental, pre-post study was designed to understand the impact of public health measures on FN admissions and outcomes in the general pediatric oncology population during the COVID (March 2020-February 2021) vs. pre-COVID era (January 2018-February 2020) and their respective respiratory seasons (November-February)...
May 2023: Pediatric Hematology and Oncology
Johanna Terrasson, Aude Rault, Étienne Seigneur, Leïla El Mellah, Sylvie Dolbeault, Anne Brédart
Announcing drug resistance is complex for pediatric oncologists because they have to provide a substantial amount of medical information while taking a major emotional impact on the parents into account. This study aimed to understand how these announcements are currently conducted and how pediatric oncologists adapt the information given to each family in situations where there is resistance to treatment. Semi-structured interviews were conducted with 15 pediatric oncologists (66.7% women, aged 44.7 years on average)...
May 2023: Pediatric Hematology and Oncology
Pia Klatt, Christin Kohrs, Barbara Stein, Markus Horneber, Daniela Reis, Jan Schildmann, Alfred Längler
Complementary and alternative medicine (CAM) use in children with cancer has a high prevalence. If (parents of) patients bring up the topic of CAM, pediatric oncologists (POs) face considerable challenges regarding knowledge and professional behavior. In this study, we explore German POs' understanding of CAM and related attitudes as well as challenges and strategies related to CAM discussions by means of semi-structured interviews analyzed according to principles of qualitative thematic analysis with parents of children with cancer...
May 2023: Pediatric Hematology and Oncology
I Kellerman, R Blaauw, J Schoeman, M Kruger
Children with cancer require adequate nutritional support to prevent malnutrition. This study investigated the impact of chemotherapy on anthropometrical status and body composition during the first six months of treatment. Anthropometrical status and body composition were measured at diagnosis, utilizing standardized protocols and validated S10 InBody bio-electrical impedance (BIA) measurements and compared to subsequent consecutive monthly follow-up measurements to plot changes over time during the first six months...
April 24, 2023: Pediatric Hematology and Oncology
Jaques van Heerden, Joyce Balagadde-Kambugu, Racheal Angom, Rebecca Claire Lusobya, Guillermo Chantada, Laurence Desjardins, Ido Didi Fabian, Trijn Israels, Vivian Paintsil, Laila Hessissen, Mame Ndella Diouf, Moatasem Elayadi, Suzanne D Turner, Francine Kouya, Jennifer A Geel
Limited survival data for the six Global Initiative for Childhood Cancer (GICC) priority cancers are available in Africa. Management of pediatric malignancies in Africa is challenging due to lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment. Reporting of outcome data is problematic due to the lack of registries. With the aim of evaluating the feasibility of baseline outcomes for the six index cancers, we present a descriptive analysis of respective survival rates in Africa...
April 2023: Pediatric Hematology and Oncology
Shevachut Chavananon, Pornpun Sripornsawan, Natsaruth Songthawee, Edward B McNeil, Thirachit Chotsampancharoen
Studies on the long-term treatment outcomes of childhood acute lymphoblastic leukemia (ALL) in resource-limited countries are scarce. The purpose of this study was to assess the evolution of survival outcomes of pediatric ALL in a tertiary care center in Thailand over a 40-year period. We retrospectively reviewed the medical records of pediatric patients who were diagnosed with ALL and treated at our center between June 1979 and December 2019. We classified the patients into 4 study periods depending on the therapy protocol used to treat the patients (period 1: 1979-1986, period 2: 1987-2005, period 3: 2006-2013, and period 4: 2014-2019)...
March 20, 2023: Pediatric Hematology and Oncology
Judy Schoeman, Ilde-Marié Kellerman, Paul C Rogers, Elena J Ladas, Carl J Lombard, Ronelle Uys, Mariana Kruger
This study investigates the prevalence of vitamin and iron deficiencies at cancer diagnosis. Newly diagnosed children between October 2018 and December 2020 at two South African pediatric oncology units (POUs) were assessed for nutritional and micronutrient status (Vit A, Vit B12, Vit D, folate, and iron). A structured interview with caregivers provided information regarding hunger and poverty risks. There were 261 patients enrolled with a median age of 5.5 years and a male-to-female ratio of 1:0.8. Nearly half had iron deficiency (47...
March 20, 2023: Pediatric Hematology and Oncology
Rebecca Ronsley, Margot Lazow, Rohan K Henry
Growth hormone deficiency (GHD) may occur in pediatric patients with central nervous system (CNS) tumors at initial tumor presentation or later as treatment-related sequelae. While it is well recognized that growth hormone (GH) has beneficial effects on growth and endocrinopathies, there's often hesitancy by clinicians to initiate GH therapy for GHD after CNS tumor diagnosis due to the perceived increased risk of tumor recurrence. The available data is described here and based on this review, there is no evidence of increased risk of tumor recurrence or secondary malignancy in patients treated with GH after CNS tumor diagnosis...
March 20, 2023: Pediatric Hematology and Oncology
Varsha Mishra, Sandeep Jain, Vaneet Anand, Payal Malhotra, Narender Tejwani, Gauri Kapoor
Prognostic predictive value of end of induction minimal residual disease (EOI-MRD) is well established in acute lymphoblastic leukemia (ALL). We evaluated the factors likely to affect EOI-MRD positivity (>0.01%) by flow cytometry and relapse in different BFM-95 (Berlin-Frankfurt-Munich) risk groups among children and adolescents. In this retrospective study, data of 223 newly diagnosed patients with ALL was analyzed. Association between demographic and pretreatment characteristics with EOI-MRD was assessed...
March 17, 2023: Pediatric Hematology and Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.